- Home
- PHGE vs ATHA Comparison
PHGE vs ATHA Comparison
Compare PHGE & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- ATHA
- Stock Information
- Founded
- PHGE 2015
- ATHA 2011
- Country
- PHGE Israel
- ATHA United States
- Employees
- PHGE N/A
- ATHA N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PHGE Health Care
- ATHA Health Care
- Exchange
- PHGE Nasdaq
- ATHA Nasdaq
- Market Cap
- PHGE 11.0M
- ATHA 10.6M
- IPO Year
- PHGE N/A
- ATHA 2020
- Fundamental
- Price
- PHGE $0.42
- ATHA $0.40
- Analyst Decision
- PHGE Strong Buy
- ATHA Buy
- Analyst Count
- PHGE 1
- ATHA 4
- Target Price
- PHGE $15.00
- ATHA $11.25
- AVG Volume (30 Days)
- PHGE 265.4K
- ATHA 226.0K
- Earning Date
- PHGE 08-13-2025
- ATHA 07-31-2025
- Dividend Yield
- PHGE N/A
- ATHA N/A
- EPS Growth
- PHGE N/A
- ATHA N/A
- EPS
- PHGE N/A
- ATHA N/A
- Revenue
- PHGE N/A
- ATHA N/A
- Revenue This Year
- PHGE N/A
- ATHA N/A
- Revenue Next Year
- PHGE N/A
- ATHA N/A
- P/E Ratio
- PHGE N/A
- ATHA N/A
- Revenue Growth
- PHGE N/A
- ATHA N/A
- 52 Week Low
- PHGE $0.34
- ATHA $0.22
- 52 Week High
- PHGE $3.86
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- PHGE 39.46
- ATHA 67.91
- Support Level
- PHGE $0.42
- ATHA $0.29
- Resistance Level
- PHGE $0.47
- ATHA $0.39
- Average True Range (ATR)
- PHGE 0.05
- ATHA 0.03
- MACD
- PHGE 0.00
- ATHA 0.01
- Stochastic Oscillator
- PHGE 47.00
- ATHA 90.57
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.